ExodusPoint Capital Management’s Editas Medicine EDIT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-261,381
Closed -$1.22M 1731
2024
Q2
$1.22M Buy
+261,381
New +$1.47M 0.01% 949
2024
Q1
Sell
-76,147
Closed -$771K 1608
2023
Q4
$771K Sell
76,147
-38,643
-34% -$339K 0.01% 903
2023
Q3
$895K Sell
114,790
-283,301
-71% -$2.43M 0.01% 1001
2023
Q2
$3.28M Buy
398,091
+373,454
+1,516% +$3.25M 0.03% 602
2023
Q1
$179K Buy
+24,637
New +$219K ﹤0.01% 1586
2022
Q4
Sell
-45,521
Closed -$557K 1741
2022
Q3
$557K Sell
45,521
-41,908
-48% -$653K 0.01% 1333
2022
Q2
$1.03M Buy
+87,429
New +$1.17M 0.01% 1063
2022
Q1
Sell
-51,369
Closed -$1.36M 2303
2021
Q4
$1.36M Buy
51,369
+1,004
+2% +$34.6K 0.01% 919
2021
Q3
$2.07M Buy
+50,365
New +$2.76M 0.03% 707
2021
Q2
Sell
-6,607
Closed -$277K 2466
2021
Q1
$277K Buy
6,607
+2,431
+58% +$138K ﹤0.01% 1723
2020
Q4
$293K Sell
4,176
-42,843
-91% -$1.76M ﹤0.01% 1555
2020
Q3
$1.32M Buy
47,019
+21,563
+85% +$702K 0.03% 565
2020
Q2
$753K Buy
+25,456
New +$665K 0.02% 884
2020
Q1
Sell
-16,697
Closed -$494K 1207
2019
Q4
$494K Buy
+16,697
New +$417K 0.01% 862

Other funds holding EDIT

ExodusPoint Capital Management's EDIT Position: Q3 2024 in Review

ExodusPoint Capital Management sold out of Editas Medicine (EDIT) in Q3 2024, closing a stake of 261,381 shares — an estimated $1.22M sold.

ExodusPoint Capital Management first reported a position in EDIT in Q4 2019 and held it in 14 quarters. The position peaked at $3.28M in Q2 2023. 229 funds tracked by Wall St. Rank hold EDIT as of Q3 2024.

  • ExodusPoint Capital Management reported no remaining Editas Medicine position as of Q3 2024 after selling out during the quarter.
  • ExodusPoint Capital Management sold 261,381 Editas Medicine shares in Q3 2024, an estimated $1.22M.
  • ExodusPoint Capital Management first reported a position in Editas Medicine in Q4 2019 and held it in 14 quarters.
  • ExodusPoint Capital Management's Editas Medicine position peaked at $3.28M in Q2 2023.
  • 229 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2024.

Based on ExodusPoint Capital Management's 13F filing for Q3 2024, filed 12 Nov 2024.